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Abstract: Neurodegenerative disorders, e.g. Parkinson’s, Huntington’s and 
Alzheimer’s diseases are distinct clinical and pathological entities sharing a 
number of leading features in their underlying processes. These common features 
involve the disturbances in the normal functioning of the mitochondria and the 
alterations in the delicate balance of tryptophan metabolism. The development of 
agents capable of halting the progression of these diseases is in the limelight of 
neuroscience research. This review highlights the role of mitochondria in the 
development of neurodegenerative processes with special focus on the 
involvement of neuroactive kynurenines both as pathological agents and potential 
targets and tools for future therapeutic approaches by providing a comprehensive 
summary of the main streams of rational drug design and giving an insight into 
present clinical achievements. 
Key words: clinical trials, drug discovery, excitotoxicity, kynurenic acid, kynurenine system, 
mitochondria, neurodegeneration, neuroprotection, quinolic acid, tryptophan metabolism. 
INTRODUCTION 
Neurodegeneration is characterized by progressive injury and loss of neurons in 
certain brain regions. The loss of function of these regions results in the development of 
distinct syndromes, e.g. Parkinson’s, Huntington’s and Alzheimer’s diseases. These disorders 
are different clinical, biochemical and histopathological entities; however, they share some 
main common characteristics such as mitochondrial dysfunction, excitotoxicity, impaired 
antioxidant capacity and disturbances in tryptophan metabolism. The presence of either 
inherited or sporadic mutations as well as chronic exposure to certain environmental factors 
can all contribute to the complex etiology of neurodegenerative disorders. The beginning of 
the pathological processes precedes the onset of clinical symptoms by years or even decades, 
thus, the possible approaches to protect neurons from progressive degeneration and cell death 
are in the focus of research in neuroscience with promising results in the preclinical but rather 
disappointing ones in the clinical phases. 
This review highlights the indisputable role of mitochondria in the development of 
neurodegenerative processes with special focus on the involvement of neuroactive 
kynurenines both as pathological agents and potential targets and tools for future therapeutic 
approaches. 
MITOCHONDRIA 
Mitochondrial structure and physiology 
Mitochondria are membrane-bound elongated organelles in the cytoplasm supposed to 
evolutionary originate from the endosymbiosis of an ancient aerobic prokaryote from the 
Proteobacteria phylum into an early eukaryotic cell [1]. A mitochondrion comprises four 
distinct compartments. The porous outer membrane, which is freely permeable to ions and 
small molecules, contains important receptors and enzymes. The invaginated and convoluted 
inner membrane with cristae contains the enzymatic apparatus of the respiratory chain and 
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oxidative phosphorylation, some essential co-factors and carrier molecules. The inner 
membrane is enriched in cardiolipin and practically impermeable to small molecules and ions 
including protons. The intermembrane space is localized between the two membranes. The 
matrix is an aqueous medium encompassed by the inner membrane. It provides environment 
for several essential metabolic pathways such as the urea cycle, β-oxidation, pyruvate 
dehydrogenase complex, citric acid cycle (Krebs–Szent-Györgyi cycle), and contains 
structural proteins, enzymes and also its own genome, the mitochondrial DNA (mtDNA). 
 Mitochondria are responsible for several physiological cellular processes such as 
energy supply, thermogenesis, calcium homeostasis, regulation of cell-cycle, development 
and aging. Biologically utilizable energy is produced by the coupled function of the citric acid 
cycle (also known as tricarboxylic acid cycle) and the enzymatic complexes (complex I–V) 
embedded in the inner membrane (reviewed in [2]). Briefly, glucose and fatty acids are 
catabolized outside the mitochondria to form pyruvate and acyl-CoA, respectively. These 
compounds are then imported to the mitochondria and transformed to acetyl-CoA that 
subsequently undergoes oxidation within the citric acid cycle to favor the formation of 
reduced coenzyme NADH and succinate through multiple enzymatic steps. These compounds 
provide electrons for complex I, II respectively, within the respiratory complex chain. 
Complexes are functionally arranged in an electrochemical hierarchy according to their 
gradually increasing electronegativity and redox potential. The “downstream” flow of 
electrons provides energy for the pumping out of protons to the intermembrane space through 
complexes I, III and IV, the latter being responsible for the reduction of molecular respiratory 
oxygen to form H2O in a process often referred as terminal oxidation. The export of protons 
from the matrix leads to the development of a proton gradient between the two compartments 
called mitochondrial membrane potential (negative inside) and an electrochemical gradient 
(alkaline inside). Since the inner membrane is impermeable to protons the electrochemical 
drive to equalize proton concentration can exclusively be achieved by the reentering of 
protons through F1F0-ATP synthase (complex V), the activation of which catalyzes the 
transformation of ADP into ATP in a process called oxidative phosphorylation [3]. ATP is a 
high-energy macromolecule that serves as the main energy source for eukaryotic cells. 
According to this chemiosmotic hypothesis mitochondria transform electrochemical energy 
into a biologically available form (Figure 1).  
Figure 1. Schematic presentation of the function and organization of the 
mitochondrial respiratory chain 
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Complex I = NADH dehydrogenase; complex II = succinate dehydrogenase; Q = coenzyme 
Q10 (ubiquinone); complex III = ubiquinol-cytochrome c oxidoreductase; c = cytochrome c; 
complex IV = cytochrome c oxidase; complex V = ATP synthase. 
Mitochondria possess their own genome in the matrix called mtDNA, which is a 
double-stranded circular DNA that is supposed to be in close relation to that of Rickettsiae. It 
contains 37 genes encoding 13 proteins, all of which are part of the respiratory complexes, 2  
ribosomal RNAs and 22 transfer RNAs [4]. Any other mitochondrial function is carried out 
by proteins encoded by nuclear DNA (nDNA) and imported into the mitochondria. The 
mitochondrial genome is almost exclusively maternally inherited due to the ubiquitination and 
subsequent degradation of paternal mitochondria in the zygote [5]. It regularly replicates in 
postmitotic cells about once in a month in humans. Mitochondrial fission is a process in 
which mitochondria grow and divide in response to an increased energy demand. In addition, 
mitochondria are prone to constant fusion with each other resulting in the mixture (and 
possibly recombination) of normal and potentially mutated genomes (“heteroplasmy”). 
Approximately 2–15 copies of mtDNA are present in a mitochondrion (“polyplasmia”) [6]. 
During cell division mitochondria are distributed randomly into the daughter cells. These 
processes, on the one hand, can protect mitochondria and their host cells from the potentially 
deleterious effects of mtDNA mutations. On the other hand, they somewhat counterbalance 
the limited possibility of genomic recombination resulting from the uniparental inheritance. 
Mitochondrial matrix can serve as a temporary buffering pool for intracellular Ca2+ 
storing it in the form of calcium phosphate, when the level of free Ca2+ in the cytosol 
increases beyond a certain set-point. After cytosolic Ca2+ level decreases below the set-point, 
Ca2+ is subsequently released from the mitochondria (reviewed in [7]). 
There is a considerable amount of evidence indicating the regulating role of 
mitochondria in apoptosis and necrosis, the former being involved in the physiological 
processes of cell-differentiation and development (reviewed in [8]). 
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Mitochondrial pathophysiology, implications in excitotoxicity and neurodegeneration 
 During the process of terminal oxidation, the efficacy of the reduction of respiratory 
oxygen to H2O is approximately 98–99%, while 1–2% of it is reduced incompletely to form 
superoxide anion (O2–•), a moderately damaging but highly reactive free radical. Free radicals 
are molecules that possess unpaired electrons in their outer orbit making them extremely 
reactive towards organic macromolecules such as DNA, RNA, lipids and proteins via 
donating their unpaired electrons to the acceptor compounds in a process called oxidative 
damage. O2–• can be transformed into hydrogen peroxide (H2O2) both spontaneously and 
through a reaction catalyzed by manganese superoxide dismutase (MnSOD). H2O2 normally 
undergoes degradation by glutathione peroxidase and catalase enzymes. If H2O2 production 
exceeds the degradation capacity, it can react with transition metals (Cu2+ and Fe2+) in the 
Fenton reaction to form a highly toxic hydroxyl radical (OH–•). O2–• is able to react with nitric 
oxide radical (NO•) to generate another highly toxic radical peroxinitrite anion (ONOO–) in a 
reaction that is three times as fast as the dismutation catalyzed by MnSOD. These toxic 
radicals are often referred to as reactive oxygen species (ROS). The major source of ROS 
production in the cell is the mitochondrial electron transport chain; however, other relevant 
sources can also be mentioned such as NADPH oxidase, myeloperoxidase, xanthine oxidase, 
monoamine oxidase, cytochrome p450 and NOS (nitric oxide synthase). 
Proteins that underwent nitrative/nitrosative or oxidative damage are particularly 
susceptible to rapid proteolytic cleavage and degradation. Damages to mitochondrial proteins 
can severely impair essential functions such as cell cycle regulation and ATP production 
(reviewed in [9]). The damage to mitochondrial respiratory complex proteins by ROS results 
in the dysfunction of electron transport that leads to two main consequences. First, it results in 
the impairment of energy supply due to the decrease in ATP production. Second, it interferes 
with the efficacy of terminal oxidation, which in turn leads to enhanced ROS production and 
the generation of a vicious circle. 
The damage to lipids caused by free radicals can interfere with normal membrane 
fluidity and may evoke the release of toxic by-products. 
The mitochondrial genome is particularly sensitive to oxidative/nitrative/nitrosative 
injury due to several reasons [10]. It is in close vicinity to the main source of ROS production, 
it is not covered by protective histones, and it contains only few non-coding sequences. 
Because of these specific features, the mutation rate for mtDNA is approximately 10-fold 
higher than that for nDNA [11]. Defensive actions of mitochondria to counteract the 
production of ROS include a repair machinery entirely encoded by nDNA, an enzymatic 
apparatus to clear reactive species (e.g. SOD, catalase, peroxidase, peroxiredoxin) and low 
molecular weight antioxidants (reviewed in [12]). In addition, severely damaged mitochondria 
can be sensed, tagged and degraded in a process regulated by PINK1 and parkin genes 
[13,14]. It should be highlighted though that some mechanisms involved in mtDNA repair, 
e.g. the activation of poly(ADP-ribose) polymerase-1 (PARP-1) can also contribute to cell 
dysfunction and death by consuming NAD+ and ATP per se [15]. The ability to cope with 
ROS-induced toxicity is thought to decline with aging [16], resulting in an increased rate of 
mtDNA point mutations and deletions in the somatic cells of the elderly [17].  
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The implications for the role of mitochondrial disturbances in neurodegenerative 
disorders come from a series of observations. First, the brain contains high amounts of 
polyunsaturated lipids that are extremely susceptible to ROS-induced lipid peroxidation; 
meanwhile, the neuronal antioxidant capacity is relatively low (reviewed in [18,19]). Second, 
the brain has an extreme energy demand accounting for 20% of total oxygen consumption, 
whereas it represents only 2% of the body mass [20]. In terms of this extremely high energy 
need, neurons show an absolute dependence on the constant availability of oxygen and 
glucose accompanied by a low capacity of glycogen storage, and a poor ability to increase 
glycolysis upon oxygen deprivation [21]. 
Glutamate is the major excitatory neurotransmitter in the human brain. The 
implications for a crucial role of elevated extracellular glutamate, and subsequent 
overactivation of ionotropic N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs) 
in the etiopathology of neurodegenerative diseases are wide and thoroughly reviewed by 
others [22]. In the case of energy impairment, e.g. due to mitochondrial dysfunction, neurons 
exhibit partial membrane depolarization that can remove Mg2+ ions blocking the ionophore 
part of the NMDARs, allowing glutamate to evoke its downstream effects even in 
physiological concentrations [23]. The activation of NMDARs results in the influx of cations, 
predominantly Ca2+ into the cytosol. Among pathological conditions, intracellular Ca2+ level 
can be so high and permanent that it exceeds the buffering capacity provided by the 
mitochondrial Ca2+ sequestration, which in turn leads to the opening of high-conductance 
mitochondrial permeability transition pores (mtPTPs) [24]. It results in subsequent 
mitochondrial swelling, loss of mitochondrial membrane potential, impaired ATP and 
elevated ROS production (reviewed in [25]), and the release of apoptosis-inducing factor 
(AIF), procaspase-9 and cytochrome c from the intermembrane space into the cytoplasm, 
where cytochrome c takes part in the formation of apoptosomes composed by cytochrome c, 
caspase-9 and apoptotic protease activating factor 1 (Apaf-1) in a process ultimately leading 
to apoptosis [26]. In addition, elevated intramitochondrial Ca2+ levels can increase the activity 
of mitochondrial nitric oxide synthase (mtNOS) to produce highly toxic NO• [27], which is 
known to impair the mitochondrial electron transport by competing with O2 for the O2-bindig 
site in complex IV [28]. Furthermore, it is capable of causing damage and cell death in 
multiple ways including the potential activation of the mtPTPs [29]. In this respect, NMDAR-
mediated Ca2+ overload can lead to mitochondrial dysfunction, enhanced ROS production, 
energy crisis and eventually cell death, which can be either apoptotic or necrotic depending on 
the severity of the initial insult [30] and the subsequent mitochondrial dysfunction [31]. 
However, it has been proposed that not the Ca2+ overload itself, but the mechanism through 
which Ca2+ ions get into the cell could be the key-holder to NMDAR-mediated excitotoxicity 
[32]. Sattler et al. have demonstrated that NMDARs are spatially linked to neuronal nitric 
oxide synthase (nNOS) by a scaffolding protein PSD-95 (postsynaptic density protein of 
molecular weight 95 kDa) allowing Ca2+ ions to evoke the synthesis of NO• in a toxic amount 
while entering into the cell upon NMDAR activation [33]. The possibly dominant role of 
nNOS in NMDAR-mediated excitotoxicity has also been supported by the results of earlier 
studies [34,35]. PSD-95 binds to the NR2B subunit of the NMDARs, which is fully consistent 
with the findings that glutamate excitotoxicity is principally mediated by NR2B subunit-
containing NMDARs [36], which predominate in the extrasynaptic sites [37], where the 
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activation of these receptors has been proven to be neurotoxic (while synaptic NMDAR 
activation seems to be protective) [38,39]. 
 The role of mitochondrial dysfunction and excitotoxicity in the process of 
neurodegeneration is clearly demonstrated (Figure 3). The development of agents being 
capable of intervening in the processes of mitochondrial dysfunction, particularly NMDAR-
mediated excitotoxicity, is one of the key features in the attempts to treat or at least positively 
influence the course of neurodegenerative diseases. 
THE KYNURENINE SYSTEM 
Certain routes of the metabolism of the essential amino acid tryptophan (TRP) are 
widely known and have been extensively studied (e.g. serotonin pathway, melatonin 
pathway), whereas the main pathway of TRP metabolism has only been in the center of 
interest for the past 40 years. In fact, the kynurenine pathway is responsible for the catabolism 
of more than 95% of TRP in the brain through a multistep enzymatic process, which involves 
the production of niacin or nicotinic acid, providing the main component of NAD+ and 
NADP+ [40,41]. The central intermediate L-kynurenine (L-KYN) is produced via the rate-
limiting step of TRP catabolism (for details, see Figure 2) and can be further metabolized 
through three distinct pathways resulting in the formation of anthranilic acid (ANA), 3-
hydroxy-L-kynurenine (3-OH-L-KYN) and kynurenic acid (KYNA). The total L-KYN 
content in the mammalian brain is about 200 ng/g [42], 60% of which is produced in the 
periphery and taken up through the blood–brain barrier (BBB) [43,44] by a large neutral 
amino acid carrier [45]. The group of “neuroactive kynurenines” (reviewed in [46]) consists 
of the three neurophysiologically relevant metabolites: KYNA, 3-OH-L-KYN and quinolinic 
acid (QUIN), the latter is formed by the further enzymatic metabolization of 3-OH-L-KYN 
and ANA [47]. 
KYNA is formed via the irreversible transamination of L-KYN by kynurenine 
aminotransferase (KAT) enzymes, which have four known distinct subtypes in the 
mammalian brain (reviewed in [48]). KAT I seems to play a limited role in the human brain 
regarding KYNA production among physiological conditions [49]; however, it is suggested 
that the neuronal expression of KAT I is involved in the regulation of development and 
apoptosis [50]. KAT II is proven to be the main enzyme of KYNA production noth in the 
human and in the rat brain, whereas it has been demonstrated to have the lowest activity in 
mice, where the main KYNA producer is KAT IV, which was found to be identical with 
mitochondrial aspartate aminotransferase (mtAAT) [51]. KAT III shares a number of 
common features with KAT I, but it has not been demonstrated to have any activity in the 
human brain [52]. Functionally, KYNA is a broad-spectrum antagonist of excitatory amino 
acid receptors with high affinity towards the strychnine-insensitive glycine coagonist site of 
NMDARs [53]. Besides, KYNA exerts a weak antagonistic effect on kainate- and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-sensitive ionotropic glutamate 
receptors [54]. However, recent reports on the effect of KYNA on AMPA receptor-mediated 
responses revealed a dose-dependent dual action, which favors facilitation in low (nanomolar-
micromolar [55], nanomolar [56]) concentrations, whilst neuroinhibition in high (millimolar 
[55], micromolar [56]) concentrations. KYNA also possesses a non-competitive inhibitory 
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effect on α7 nicotinic acetylcholine receptors [57] through which KYNA is involved in the 
negative regulation of presynaptic glutamate release [58]. Moreover, KYNA increases the 
expression of non-α7 nicotinic acetylcholine receptors [57]. As a modulator of glutamate 
activity KYNA is proposed to be one of the endogenous neuroprotective agents (widely 
reviewed by Zadori et al. [59]). The dose-dependent neuroprotective efficacy of KYNA has 
been postulated and confirmed in a number of animal paradigms including kainate- [60,61], 
ibotenate- [61], QUIN- [61,62] and NMDA-induced neurotoxicity [61,63,64]. Furthermore, 
KYNA appears to possess a potent anticonvulsant effect even in physiological concentrations 
[65]. The effect of KYNA to block the activity of NMDARs is in accordance with the typical 
findings of behavioral studies subsequent to its intracerebroventricular administration in rats 
[66,67]. Additionally to its widely demonstrated anti-excitatory efficacy, KYNA has most 
recently been described as a potent free radical scavenger and antioxidant in vitro and in vivo 
[68]. 
QUIN is a specific, but rather weak and low-affinity competitive agonist of NMDARs 
that contain NR2A and NR2B subunits [69]. In contrast to KYNA, QUIN has proved to be 
neurotoxic in a number of animal paradigms and seem to exert its deteriorating effects on 
multiple ways including NMDAR activation [70], presynaptic glutamate release enhancement 
[71,72], astrocytic glutamate uptake inhibition [72], endogenous antioxidant depletion [73], 
ROS production [74] and lipid peroxidation [75]. The probable dominant role of NMDAR 
activation in QUIN-induced toxicity is supported by the findings that the activation of NOS 
enhances, its selective inhibition decreases [76], whereas the NMDAR blocker MK-801 
completely abolishes lipid peroxidation induced by QUIN [77]. 
The detrimental effects of 3-OH-L-KYN have proven to be independent from 
NMDAR functioning but are rather due to its intracellular uptake and subsequent ROS 
production [78], and are at least partly mediated by its neurotoxic metabolite 3-OH-ANA, 
which is prone to undergo auto-oxidation in a process resulting in superoxide production [79]. 
The intrastriatal co-administration of 3-OH-L-KYN and QUIN in subtoxic doses revealed a 
synergistic effect of these compounds leading to a substantial loss of neurons, which provides 
evidence that the presence of 3-OH-L-KYN can increase the risk of neurodegeneration during 
excitotoxic insults if QUIN is involved in the process [80]. 
It is noteworthy to mention that the different types of glia cells preferentially express 
or quite conversely lack the expression of certain enzymes in the metabolic pathways. 
Astrocytes, the major producers of KYNA in the CNS, are known to lack kynurenine 3-
monooxygenase (KMO, kynurenine 3-hydroxylase) in favor of the synthesis of KYNA, 
whereas microglial cells and macrophages exhibit low KAT enzyme expression, which offsets 
the balance of TRP metabolism towards the direction of QUIN. A paradox role of astrocytes 
is revealed when surrounded by microglial cells or macrophages that can produce toxic 
amounts of QUIN from L-KYN excessively generated by astrocytes [81]. These preferences 
may contribute to the higher resistance of astrocytes against excitotoxic and ROS-generating 
stimuli, and also to their involvement in neuroprotection. In addition to the recent findings 
that TRP metabolism and KYN pathway possess a key regulatory role in the processes of 
immune response and tolerance (reviewed in [82]), these data provide a deeper insight into the 
role of inflammation accompanied by microglial and macrophage infiltration in the 
pathogenesis of neurodegenerative disorders. 
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Figure 2. The metabolism of tryptophan 
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Due to the fact that KYNA itself poorly penetrates the BBB [45], and has a limited 
selectivity and affinity towards the glycine-binding site of the NMDARs [83], a number of 
pharmaceutical approaches have been established to exploit its therapeutic potential. These 
approaches include three mainstream strategies. The first is the synthesis of KYNA analogues 
and prodrugs (reviewed in [84]). The most frequent molecular modifications result in 
halogenated KYNA analogues (e.g. 7-Cl-KYNA [85]) and its BBB-penetrant prodrug 4-Cl-
KYN [86,87]), thiokynurenates [88], sugar conjugates of KYNA or its analogues (e.g. D-
galactose-7-Cl-KYNA, D-glucose-7-Cl-KYNA [89] and glucosamine-KYNA [90,91]) and 
most recently kynurenic acid amides [92-96] that are proposed to be selective inhibitors of 
NR2B subunit-containing NMDARs [97]. Halogenated and thio-substituted derivatives 
possess increased selectivity and affinity towards the glycine-binding site of NMDARs [98], 
whereas the conjugation with sugars increases the penetration through the BBB via 
“hitchinking” on sugar transporter molecules [89]. The second strategy represents the 
systemic administration of L-KYN, which is known to penetrate the BBB better. L-KYN 
either alone or in combination with probenecid (an inhibitor of transmembrane organic acid 
transport) has been proven to be neuroprotective [99-102] and anticonvulsive [103,104] 
serving as a non-selective precursor for astrocytic KYNA synthesis. The co-administration of 
probenecid is a widely applied technique to overcome the rapid clearance of L-KYN, 
kynurenic acid and its derivatives [105]. The third main approach is the specific modulation 
of enzyme activities involved in TRP metabolism towards the enhancement of protective 
KYNA synthesis and attenuation of the detrimental metabolites QUIN and 3-OH-L-KYN. 
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The three main targets of enzyme inhibitors are KMO, kynureninase and 3-hydroxyanthranic 
acid 3,4-dioxygenase (3-HAO). Nicotinylalanine was one of the first potent KMO inhibitors 
with a relatively small specificity [100,106,107]. The most widely used KMO inhibitors with 
enhanced specificity include (m-nitrobenzoyl)alanine [108], 4,5-dichlorobenzoylalanine 
(PNU 156561, formerly referred as FCE 288833A) [109], (1S,2S)-2-(3,4-dichlorobenzoyl)-
cyclopropane-1-carboxylic acid (UPF 648) [110], 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-
2-yl]-benzenesulfonamide (Ro 61-8048) [111] and most recently its prodrug 2-(3,4-
dimethoxybenzenesulfonylamino)-4-(3-nitrophenyl)-5-(piperidin-1-yl)methylthiazole (JM6) 
[112], which is presumed to overcome the rapid diminish of Ro 61-8048 from the circulation. 
The inhibition of kynureninase is achieved by structural analogues of its substrate L-KYN 
including (4R)- and (4S)-dihydro-L-KYNs [113], S-aryl-L-cystein S,S-dioxides [114], 
byciclic L-KYN analogues [115], phosphinic acid L-KYN analogues [116], (o-
methoxybenzoyl)alanine [117] and desaminokynurenine derivatives [118]. Notably the KMO 
inhibitors nicotinylalanine and (m-nitrobenzoyl)alanine also affect the activity of 
kynureninase [119]. The third related enzyme 3-HAO can be inhibited by the structural 
analogues of 3-hydroxy-anthranilic acid (3-OH-ANA). The most widely studied derivatives 
are the 4-halogenated [120] and 4,6-dihalogenated 3-OH-ANAs, among which 4,6-dibromo-
3-OH-ANA (NCR-631) has deserved a great attention for its potent neuroprotective, anti-
inflammatory [121] and anticonvulsant [122] properties, especially since the applied dose has 
been shown to cause no alteration in brain QUIN and KYNA levels by the same research 
group [123]. Interestingly, (o-methoxybenzoyl)alanine, a selective kynureninase inhibitor can 
exert inhibition on 3-HAO as well, in a process depending on the presence of mitochondria 
[124]. The KYNA analogue prodrug 4-Cl-KYN is also able to exert potent inhibition on 3-
HAO through its metabolite 4-Cl-3-OH-ANA [125]. Though the inhibition of these enzymes 
can influence the syntheses of both KYNA and QUIN, it has been implicated that the 
reduction of QUIN levels could be more important than the elevation of KYNA regarding 
their protective features [126].  
Although they seem to be rather secondary to the underlying processes, the alterations 
in the delicate balance of TRP metabolism between the pathways towards KYNA and QUIN 
production can possess a crucial role in the development of certain neurodegenerative 
diseases. Selective manipulations of the kynurenine system might harbor valuable therapeutic 
potential. 
PARKINSON’S DISEASE 
 Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder 
characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc), the decrease of dopamine and its metabolites in the striatum and the presence of 
Lewy bodies [127]. Clinical symptoms include bradykinesia, rigidity, resting tremor and 
postural instability [128,129]. The development of Parkinson’s disease has been associated 
with the complex interplay of environmental and genetic factors. We can distinguish between 
idiopathic/sporadic and familial PD. A number of genes have been associated with the 
development of familial PD (PARK genes) (reviewed in [130]), most of them having direct 
implications in mitochondrial dysfunction. 
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Mitochondrial dysfunction in PD 
The involvement of mitochondrial dysfunction in the pathogenesis originates from the 
discovery of the synthetic drug side-product 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), the administration of which has been found to almost perfectly recapitulate 
parkinsonian symptoms and pathology with the exception of Lewy body formation [131]. 
Accumulating within the mitochondria MPP+ (1-methyl-4-phenylpyridinium), the active 
metabolite of MPTP impairs the activity of complex I [132] selectively in the dopaminergic 
neurons of SNpc [133]. The inhibition of electron transport in these neurons has become the 
main animal model of PD. Besides MPTP intoxication, selective mitochondrial dysfunction 
can be achieved by known environmental pesticides such as the natural insecticide rotenone, 
the quaternary ammonium herbicide paraquat, and the manganese-containing dithiocarbamate 
fungicide maneb, which are capable of inhibiting complex I, I and III, respectively (widely 
reviewed in [134]). Human studies regarding the activity of electron transport complexes in 
platelets, muscle cells, SNpc and cortical neurons have provided contradictory findings. 
Although systemic complex I deficiency still seems to be a predominant feature in the 
development of PD [135], recent findings have questioned its primary role in the 
pathomechanism of PD-related toxins [136]. 
  Epidemiological studies (reviewed in [137]) along with recent genome-wide single 
nucleotide polymorphism (SNP) analyses [138] have indicated that the development of 
idiopathic PD is rather due to environmental factors than mere genetic heritability; however, 
the presence of certain mtDNA and nDNA mutations has been associated with this form of 
the disease including the polymorphisms in mtDNA polymerase gamma 1 (POLG1) 
[139,140] and complex I subunit ND5 [141]. On the other hand mtDNA haplotypes J and K 
[142] and the haplotype cluster UKJT [143] have been reported to be protective for their 
carrier population. 
 The majority of gene mutations found to be causative in familial PD can be associated 
with mitochondrial dysfunction. The gain-of-function mutation of PARK1 leads to extensive 
mitochondrial accumulation of its product α-synuclein [144], the main constituent of Lewy 
body inclusions, leading to the inhibition of complex I in vitro [144], in vivo [145] and in post 
mortem human studies [144]. The interaction of α-synuclein with complex IV has also been 
demonstrated [146]. Its transgenic overexpression in mice results in increased vulnerability 
against mitochondrial neurotoxins paraquat and MPTP [147], whereas α-synuclein knock-out 
mice are resistant to MPTP and intriguingly to 3-nitropropionic acid (3NP) and malonate as 
well, which are mitochondrial toxins widely used in modeling Huntington’s disease [148]. 
However, there seems to be a bidirectional relationship between mitochondrial dysfunction 
and α-synuclein since the impairment of mitochondrial function itself can lead to the 
formation of α-synuclein inclusion bodies [149]. The product of PARK2 gene parkin is 
involved in the polyubiquitin tagging of potentially dangerous and aggregation prone protein 
substrates for proteosomal degradation via its ubiquitin E3 ligase activity [150]. Its potential 
mitochondrial function includes the maintenance of physiological antioxidant status by the 
regulation of gluthatione metabolism [151] and SOD activity [152]. Parkin is suggested to be 
involved in mitochondrial replication and transcription as well, through a direct association 
with mitochondrial transcription factor A (TFAM) [153]. Its overexpression has demonstrated 
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the important role of parkin in mitochondria-dependent cell death via the inhibition of 
cytochrome c and caspase 3-mediated apoptosis [154], and has proven to be effective in 
rescuing mitochondrial dysfunction caused by PINK1 loss-of-function [155]. Animal knock-
out models of parkin exhibit severe mitochondrial degeneration accompanied by the 
decreased expression of several subunits of complex I and IV [156,157], but, interestingly, no 
increase in the susceptibility against MPTP intoxication has been reported [158]. PARK6 
encodes the phosphatase and tensin homologue (PTEN)-induced putative kinase 1 (PINK1). 
PINK1 loss-of-function exhibits similar features with that of parkin including the phenotype 
of mitochondrial degeneration [159], and the decrement in the activity of mitochondrial 
complexes [160]. It is suggested that PINK1 and parkin share a common mechanistic pathway 
with PINK1 acting upstream of parkin [161] in a number of mitochondrial processes 
including the regulation mitochondrial dynamics [13,14]. Contrary to parkin, the defect of 
PINK1 has recently been reported to increase the extent of toxicity in MPP+/MPTP 
paradigms [162]. PINK1 is able to prevent the release of cytochrome c and subsequent 
apoptosis via the phosphorylation of its substrate TRAP1 (tumor necrosis factor receptor-
associated protein 1) in vitro [163]. The involvement of PINK1 in the regulation of cell death 
is further highlighted by the finding that mtPTPs can open up even due to physiological 
calcium stimuli in PINK1-deficient cells [164]. High temperature requirement factor A2 
(HtrA2 or Omi), the product of PARK13 gene also acts downstream of PINK1 in preventing 
mitochondrial dysfunction [165]. Omi has been demonstrated to serve as a mitochondrial 
protein quality controller and a regulator of autophagy [166]. Knock-out of PARK13 results 
in selective striatal neuronal loss and parkinsonian motor deficits in mice [165]. PARK7 
protein DJ-1 is suggested to be an oxidative stress sensor being capable of modulating 
mitochondrial transcription and glutathione metabolism during mitochondrial stress [167]. 
The loss of its function results in impaired ROS scavenging [168] and increased susceptibility 
to MPTP [169], paraquat and H2O2-induced mitochondrial toxicity [170]. Recently, DJ-1 has 
also been identified as a deregulator of astrocytic inflammatory processes [171]. DJ-1 seems 
to work in parallel with PINK1/parkin pathway to maintain mitochondrial function during 
oxidative environment [172]. Furthermore, a definite complex interplay has recently been 
suggested between these three PD-related proteins (called PPD complex) in the degradation of 
misfolded/unfolded proteins; however, this hypothesis warrants further investigations [173]. 
Apart from the knowledge that PARK8 protein leucine-rich repeat kinase 2 (LRRK2) has been 
found to co-localize with membrane bound intracellular structures including mitochondria 
[174], little has been known about its role in mitochondrial pathology until very recently. 
Human [175] and in vivo studies [176] indicate that the LRRK2 mutation G2019S, the most 
common mutation in both familial and sporadic PD is associated with impaired mitochondrial 
function and morphology [175] and an enhanced sensitivity to mitochondrial stressors [176]. 
 A number of pre-clinically effective drug candidates against mitochondrial 
dysfunction in PD have already reached the clinical phases (widely reviewed by Klivenyi et 
al. [177]. The phase II safety-trial of inosine (SURE-PD), the BBB-penetrant precursor of the 
natural antioxidant uric acid, is on its way, based on the retrospective observation of two prior 
clinical studies (DATATOP [178], PERCEPT [179]) that high normal levels of serum uric 
acid provided marked suppression on the rate of clinical progression. 
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Coenzyme Q10 or ubiquinone is another potent antioxidant physiologically 
functioning as an electron acceptor that transfers electrons from complex I and II to complex 
III in the respiratory chain. After its efficiency has been proven in in vitro and in vivo models 
of parkinsonism [180-182], Q10 seems to slow disease progression in patients with early PD 
but not in midstage PD according to the results of the completed phase II [183] and phase III 
[184] clinical studies. A phase III trial (QE3) with larger doses is currently running; however, 
the recent negative findings with the mitochondria targeted quinone derivative MitoQ 
suggests little hope [185]. 
The neuroprotective efficacy of creatine via buffering energy deficit in mitochondrial 
dysfunction has been demonstrated in a number of neurodegenerative animal models (widely 
reviewed by Beal et al. [186]) including MPTP [187,188] and rotenone [189]; furthermore, its 
co-administration with coenzyme Q10 has provided an additive neuroprotection in chronic 
MPTP paradigm [190]. Creatine has already proved to be non-futile [191] and safe [192] in a 
phase II clinical trial (NINDS NET-PD) and has showed ~50% improvement in Unified 
Parkinson's Disease Rating Scale at one year. The phase III trial is currently ongoing (NET-
PD LS-1). 
Peroxisome proliferator-activated receptor-γ (PPARγ) coactivator-1α (PGC-1α) 
possesses a key integratory role in the transcriptional control of cellular energy metabolism, 
mitochondrial function and biogenesis, and oxidative stress defense (reviewed in [193]). 
PGC-1α knock-out mice exhibit increased vulnerability against both MPTP and kainic acid 
treatment [194], whereas its overexpression protects neurons against mitochondrial 
dysfunction due to mutant α-synuclein [195] and rotenone [195]. Correspondingly, the 
underexpression of genes depending on the function of PGC-1α system has also been 
demonstrated in human patients with Parkinsons’s disease in a very recent genome-wide 
meta-analysis [195], and an SNP study has revealed possible associations of PGC-1α 
polymorphisms with risk, age of onset and longevity in PD [196]. Pioglitazone, a widely 
known agonist of PPARγ enhances the activity and expression of PGC-1α [197], besides it 
exerts transcriptional repression on a range of inflammatory proteins (reviewed in [198]). It 
has already proved its efficacy MPTP studies [199,200] and the phase II safety and futility 
clinical trial is already recruiting its participants with early Parkinson’s disease 
(NCT01280123). 
SNpc neurons possess specific vulnerability against the engagement of L-type 
Ca(v)1.3 Ca2+ channels due to subsequent mitochondrial oxidative stress [201]. Blocking 
these channels by isradipine showed neuroprotective efficacy in animal models of PD 
[202,203] without impairing the autonomous pacemaking activity of SNpc neurons [204]. 
Moreover, isradipine has proven to be of therapeutic use against L-DOPA-induced 
dyskinesias [205]. A phase II clinical trial examining the safety and the efficacy of isradipine 
administration in PD patients has just been finished (NCT00753636), another one is currently 
active (STEADY-PD). 
PD and the kynurenine system 
 Considering that SNpc receives glutamatergic inputs from a number of cortical and 
subcortical regions including the cerebral cortex, subthalamic nucleus and amygdala 
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(reviewed in [206]), and that complex I deficiency results in increased sensitivity to 
excitotoxic insults in SNpc of PD patients [135], furthermore, that the role of mitochondrial 
NO• accumulation in PD has recently emerged (reviewed in [207]), it is understandable that 
an increasing interest is focusing on the potential roles of endogenous neurotoxins and 
neuroprotectants of the kynurenine system in the pathogenesis of the disease. 
 The systemic administration of MPTP has been demonstrated to decrease KAT I 
activity in murine SN [208], and ex vivo rat cerebral cortical slices show diminished activity 
of KAT II and subsequent decrease in KYNA following MPP+ insult [209]. Consistent 
human post mortem studies of PD brains have reported decreased KYNA level and L-KYN/3-
OH-L-KYN ratio in the putamen, SNpc and the frontal cortex, and elevated 3-OH-L-KYN 
level in SNpc and the putamen [210]. Plasma levels of QUIN have also been found to be 
elevated in PD patients [211]. The switch of TRP metabolism to the direction of 3-OH-L-
KYN and QUIN might be secondary to the inhibited state of complex I and subsequently 
increased NAD+ demand, and it may contribute to further nigrostriatal degeneration by 
enhanced excitotoxicity and oxidative stress.  
 Interestingly, there seems to be a physiological inverse regulation between striatal 
KYNA and dopamine levels. Systemic administration of L-DOPA [212] and D-amphetamine 
[213] causes a decrease in KYNA levels in the rat brain. On the other hand, exhibits indirect 
inhibition on dopamine release KYNA in nanomolar concentrations by blocking astrocytic α7 
nicotinic acetylcholine receptors, whereas direct inhibition in higher concentrations through 
blocking NMDARs and non-NMDARs [214]. In addition, the selective inhibition of KAT II 
leads to a two- to threefold increase in extracellular striatal dopamine level, which can be 
rescued by the co-infusion of KYNA [215]. Thus, dopaminergic stimulation, e.g. by D-
amphetamine or L-DOPA can theoretically and experimentally result in higher striatal 
vulnerability against excitotoxic insults further deteriorating nigrostriatal degeneration [216]. 
However, chronic admininistration of L-DOPA, which is the first-line symptomatic therapy in 
PD, has previously been demonstrated by others to have no deteriorating effect on the 
remaining nigrostriatal neurons [217]. 
 The co-infusion of nicotinylalanine, L-KYN and probenecid into SNpc provides 
protection against neurotoxicity induced by locally administered NMDA and QUIN in rats 
[100]. Furthermore, the bilateral injection of KYNA to the medial segment of globus pallidus 
of severely parkinsonian MPTP-treated monkeys [218,219] and rats [219] alleviate motor 
symptoms such as akinesia, tremor and rigidity in a dose-dependent manner [219]. 
Taken together, the long-term pharmacological increase of brain KYNA levels might 
be beneficial in PD due to its neuroprotective potential; furthermore, it has been proven to be 
effective in treating L-DOPA-induced dyskinesias without compromising the 
antiparkinsonian effect of chronic L-DOPA therapy in monkeys [220]. 
HUNTINGTON’S DISEASE 
 Huntington’s disease (HD) is a chronic inherited autosomal dominant 
neurodegenerative disorder characterized by the preferential loss of the striatal γ-aminobutyric 
acidergic (GABAergic) medium-sized spiny neurons (MSNs) and the appearance of 
intranuclear and intracytoplasmic aggregates of mutant huntingin protein widely distributed in 
15 
 
neuronal and extaneuronal tissues. The clinical symptoms appear around the mid 40s 
manifesting in hypotonic hyperkinesias (chorea, ballism) in early stages, becoming 
accompanied by dystonia, pyramidal symptoms, psychosis and dementia as the disease 
progrediates. 
Mitochondrial dysfunction in HD 
The association of HD with deficient activity of mitochondrial complex II was very 
early revealed by a human post mortem examination [221], whereas later studies reported the 
involvement of complex III and IV as well [222,223]. The effect of mitochondrial dysfunction 
and subsequent oxidative stress to cellular compartments can be observed in the increased 
number of mitochondrial mutations in HD patients [224]. The inhibition of complex II either 
irreversibly by 3-nitropropionic acid (3NP) [225] or reversibly by malonate [226] is widely 
applied in modeling HD in vivo. Systemic intoxication by 3NP has been shown to effectively 
recapitulate most of the clinical and histological characteristics of HD, including preferential 
neurodegeneration of GABAergic MSNs in the striatum [227]. Meanwhile the relevance of 
the malonate model as a preclinical screen has recently been questioned due to the poor 
reflectivity of its results to that of transgenic HD models [228].  
Huntingtin protein is encoded by the IT15 (interesting transcript 15) gene localized in 
the short arm of chromosome 4, and the pathognomonic polyglutamine (polyQ) repeat-
containing mutant variant develops due to the expansion of its CAG trinucleotid repeat 
sequence. The number of CAG repeats strongly correlates with clinical severity [229]. Mutant 
huntingtin is able to directly bind to mitochondria [230] and appears to be causative in HD 
due to its toxic gain of function resulting in mitochondrial dysfunction through many ways 
including the transcriptional repression of PGC-1α [231], the dysregulation of mitochondrial 
trafficking [232], and the impairment of mitochondrial Ca2+ handling [233] with increased 
susceptibility to Ca2+-induced permeability transition and cytochrome c-mediated apoptosis 
[234,235]. However, an increasing amount of evidence suggests a differential effect of mutant 
huntingtin inclusions to cell survival, causing neurodegeneration in the form of small 
aggregates or aberrantly folded monomers, whilst being protective as larger aggregates 
probably via the sequestration of the toxic forms [236]. Furthermore, it is suggested that the 
relatively late symptomatic onset of an early expressing genetic mutation is due to a sort of 
compensatory mechanism induced by mutant huntingtin, the effect of which can be seen in 
the prominent resistance of young R6/2 transgenic HD animals against QUIN [237], kainic 
acid [238], 3NP [239] and malonate [240] compared to wild-type littermates or more aged 
mutants [241]. Indeed, the enhanced sensitivity of the striatum of R6/2 animals to 
glutamatergic exctitotoxicity appears to be age-dependent and correlates with decreased levels 
of glutamate transporters within the striatum [242]. 
Serious efforts have been made to find drug candidates capable of overcoming 
mitochondrial dysfunction in HD. Similarly to its results in PD, coenzyme Q10 provides 
contradictory findings in HD both in preclinical and clinical levels of investigation. While a 
number of authors have reported significant neuroprotection by means of decrease in 3NP-
induced striatal lesions [190,243] and improvement in both survival and motor performance in 
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transgenic HD mice [190,244], other groups investigating transgenic animal models either 
report amelioration only in motor performance, but not in survival [245], or find no 
significant differences in any endpoint [246,247]. A most interesting, recently published 
comprehensive study has proposed that the reported beneficial effects of coenzyme Q10 on 
survival and motor performance of transgenic mice could be due to inappropriate husbandry, 
when HD pathology could interfere with adequate nutrition and secondarily lead to coenzyme 
Q deficiency [247]. The first human multicenter clinical trial with Q10 (CARE-HD) showed a 
non-significant tendency to slow functional decline in HD [248]. Having proven its safety and 
tolerability in higher doses (Pre2CARE) [249], Q10 is currently running in a larger phase III 
study with 2.4 g/day oral administration (2CARE) along with a phase II prevention study 
(PREQUEL) for pre-manifest HD patients. 
Likewise in PD, the antioxidant and energy buffer creatine has showed promising 
neuroprotective efficacy in animal models of HD [190,250] and has been reported to dose-
dependently inhibit polyQ aggregation in a slice culture assay [251]. Furthermore, creatine-
kinase has recently been proposed as a biomarker for the deterioration of HD pathology as it 
has been found to be reduced in 3NP-intoxicated rats [252], in transgenic HD mice and in HD 
patients in a disease severity-dependent manner [253]. Its oral administration has proven to be 
safe, tolerable, and beneficial for the antioxidant status in HD [254]. However, up to now, 
clinical trials with orally administered creatine have failed to reveal any improvement in the 
cognitive, functional and neuromuscular status of HD patients [255-257]. A phase II and a 
phase III clinical trial were initiated in 2007 and 2009 to evaluate tolerability and efficacy of 
higher doses of creatine in pre-manifest (PRECREST) and manifest (CREST-E) HD, 
respectively. 
L-carnitine is involved in the mitochondrial exchange of fatty acids and harbors 
effective antioxidant properties (reviewed in [258]). It is able to suppress 3NP-induced 
permeability transition in isolated mitochondria [259] and has recently been found effective in 
a transgenic mouse model of HD [260]. A double-bind crossover study with only few 
participants enrolled has revealed no significant effect of acetyl-L-carnitine on clinical status 
of HD patients [261]. A large, randomized, double-blind, placebo-controlled clinical trial to 
elucidate the therapeutic potential of L-carnitine is warranted. 
Cysteamine and its oxidized form cystamine are potent antioxidants and can exert 
neuroprotection via pleiotropic actions including the maintenance of antioxidant status [262-
264] and the elevation of brain-derived neurotrophic factor (BDNF) secretion [265], a growth 
factor known to be deficient in HD-related CNS regions [266]. Both compounds have shown 
neuroprotective efficacy in in vitro [267] and in vivo models of HD [252,264,268,269]. It is 
known that the level of tissue transglutaminase enzyme is elevated in HD models in vitro 
[270], in vivo [268] and also in HD patients [271,272]. The long-held presumption that the 
ability of cystamine to inhibit transglutaminase activity [269,273] would be responsible for its 
neuroprotective effect has recently been challenged [274], along with the hypothesis that this 
enzyme would contribute to disease progression via cross-linking huntingin and promoting its 
aggregation [275]. Having completed a phase I dose finding and tolerability study (CYTE-I-
HD) [276], a phase II clinical trial with delayed release cysteamine RP103 is ongoing. 
 HD patients and transgenic HD mice exhibit similar metabolic disturbances 
manifesting in a hypercatabolic status [277] with marked weight loss [278], which precedes 
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the development of motor symptoms [277] and appears to be directly related to the number of 
CAG repeats [279]. The involvement of impaired PGC-1α expression in the development of 
metabolic disturbances is assumed [280]. Dietary n-3 polyunsaturated fatty acids (PUFAs), 
such as eicosapentaenic acid (EPA), are known to improve mitochondrial metabolism in many 
ways, including the activation and induction of the PPAR family (PPARα, -β, -γ1, -γ2) and 
PGC-1α [281] besides other key transcription regulatory proteins (widely reviewed in [282]). 
Early and sustained treatment with PUFAs has been able to diminish behavioral alterations in 
R6/2 transgenic mice fundamentally [283], but the administration of ethyl-EPA to mature 
YAC128 transgenic mice could only result in modest but significant behavioral improvement 
[284]. Oral administration of PUFAs resulted in significant improvement in dyskinesias, 
which is the first report of a significant improvement achieved in a randomized clinical trial in 
HD [285]. Despite its peerless effect to prevent atrophy of the affected brain regions [286], 
ethyl-EPA treatment has shown no clinical benefit in a randomized, double-blind trial [287]. 
A multicenter, randomized trial was initiated in 2008 to re-evaluate the clinical efficacy of 
ethyl-EPA in HD (TREND-HD) and reported no benefit after the first six months [288]. 
 Dysfunctional epigenetic regulation is considered to be another substantial component 
in the pathogenesis of HD. Accordingly, various histone deacetylase inhibitors have been 
found protective in animal models of HD [289,290]. D-β-hydroxybutyrate, a mitochondrial 
energizing keton body, has recently been found protective in 3NP and transgenic HD models, 
which effects were accompanied by the inhibition of histone deacetylation mediated by 
mutant huntingtin [291]. These findings indicate that D-β-hydroxybutyrate may confer 
neuroprotection via simultaneously targeting the mitochondrial and epigenetic alterations 
associated with HD, which makes this compound a valuable candidate of investigation in 
clinical trials to come. 
HD and the kynurenine system 
Early observations with exogenous [292,293] and endogenous [294,295] excitotoxins 
raised the suggestion that striatal excitotoxicity may take the lead in the development of HD. 
This hypothesis has gained support by the results of a subsequent human postmortem study 
revealing a massive loss of NMDAR binding in the striatum [296]. Indeed, the preferential 
abundance of NR2B subunit containing NMDARs on striatal neurons [297,298] and the 
innate hypersensitivity of their mitochondria to Ca2+ overload-induced permeability transition 
[299] along with the robust glutamatergic input of the striatum from the thalamus and the 
cerebral cortex [300] make this brain region a particularly vulnerable structure to 
glutamatergic excitotoxicity. While normal huntingtin exhibits neuroprotection against 
NMDA-induced neurotoxicity via binding to the scaffolding protein PSD-95, polyQ-
expanded mutant huntingtin exaggerates the toxicity by inhibiting this interaction [301]. 
Furthermore, mutant huntingtin has been reported to increase the expression [302] and 
enhance the tyrosine phosphorylation of NR2B subunit-containing NMDARs [303], further 
contributing to the enhanced sensitivity. Very recently, the increased expression and activity 
of these extrasynaptic NMDARs in transgenic HD mice has been reported [304], which is 
associated with decreased striatal cyclic AMP response element-binding protein (CREB) 
signaling [304] and subsequent underexpression of PGC-1α [298]. Considering that the 
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enhanced sensitivity of NMDARs in HD striatum appears to be accompanied by decreased 
glutamate uptake in both transgenic HD mice [305] and the human HD brain [229], the 
demand for regulating NMDAR function makes the kynurenine system a rational target for 
investigation. 
It has become evident very early that the intrastriatal administration of QUIN provided 
a fairly good model for HD [294,295,306], as it evokes cognitive, motor and neurochemical 
alterations closely resembling that of the human disease. It is a reasonable question whether 
this endogenous neurotoxin may play a role in the development of HD itself. Indeed, human 
studies have revealed multiple alterations in TRP metabolism in HD. On the one hand, QUIN 
[307] and 3-OH-L-KYN levels have been were found to be elevated in the human HD brains, 
particularly in the striatum [307]. Noteworthly, these alterations are apparent only in early 
stages of HD, and the results from studies not adjusted to the stage are fairly controversial 
[308,309]. Nevertheless, the role of QUIN and 3-OH-L-KYN in the initial stage of 
neurodegeneration in HD seems reasonable, and is in line with the observation that 
intrastriatally injected QUIN evokes effects that mimic earlier symptoms of HD [310]. 
Alterations in TRP metabolism including the abnormally high activity of the biosynthetic 
enzymes of QUIN and 3-OH-L-KYN have also been demonstrated in transgenic HD mice 
[311]. On the other hand, striatal [312], cortical [313] and cerebrospinal fluid (CSF) [309,312] 
KYNA levels have been reported to be decreased in HD patients, paralleled by decreased 
activity of the relevant KATs [312,314]. The findings that 3NP reduces KAT-I and KAT II 
activities in experimental rat models [209,315] indicate that the alterations of TRP 
metabolism might be secondary to the mitochondrial energy crisis present in HD. In such 
hypersensitive conditions to NMDAR-mediated toxicity, these alterations could easily 
contribute to the further deterioration of the neurodegenerative process. Indeed, the replication 
of these alterations in a KAT II knock-out mice model has demonstrated increased striatal 
vulnerability to QUIN [110], similarly to a transgenic HD model [316]. Correspondingly, the 
genetic ablation of the KAT II homologue ARO9 enhances the toxic effect of mutant 
huntingtin in yeasts, whereas the ablation of KMO homologue BNA4 provides protection 
[317]. Another research group has reported that the genetic inhibition of either KMO or 
tryptophan 2,3-dioxygenase (TDO) is neuroprotective in transgenic HD flies [318]. There is 
experimental evidence that pharmacological elevation of KYNA is neuroprotective in HD. 
The efficacy of the BBB-penetrant KYNA derivative prodrug 4-Cl-KYN [86] and the KMO 
inhibitor nicotinylalanine [107] has already been proven against striatal neurodegeneration 
induced by malonate [86] and QUIN [86,107] in rats, and a recently published study has 
demonstrated extended survival and neuroprotection in transgenic HD mice by a novel KMO 
inhibitor prodrug JM6 [112]. 
Pharmacological regulation of NMDAR activity is a double-edged sword due to its 
ubiquitous function in the CNS; furthermore, evidence suggests that the inhibition of synaptic 
NMDARs is neurotoxic via blocking BDNF and CREB pathways [38]. However, the cautious 
dosing of NMDAR blockers can overcome this issue and protect transgenic HD mice by the 
preferential blockage of extrasynaptic NMDARs [298,304]. Our laboratory has recently 
reported the massive neuroprotective efficacy of a novel KYNA amide N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride [93] in N171-82Q 
transgenic HD mice [96], which can be a perfect candidate drug since KYNA amides may 
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preferentially inhibit NR2B-containing NMDARs [97], which predominate in the 
extrasynaptic areas. The preclinical screening of other newly synthesized KYNA amides is 
underway, searching for the most valuable candidates for future clinical investigations. 
ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is also a classic, chronic, neurodegenerative disorder 
characterized by hippocampal, cortical and basal forebrain cholinergic neurodegeneration and 
atrophy with late-onset progressive dementia, which manifests in the loss of short-term and 
spatial memory and eventually most of the cortical functions. The process is accompanied by 
the formation of predominantly extracellular plaques of β-amyloid (Aβ) and predominantly 
intracellular deposits of neurofibrillary tangles (NFTs) constituted by hyperphosphorylated 
tau proteins (pTau). AD is the most common cause of dementia (50–60%), affecting 
approximately 30% of the elderly in the developed world. AD is typically a sporadic disease; 
familial forms are very rare and are characterized by presenile onset (reviewed in [319]). 
Mitochondrial dysfunction in AD 
A significant decrease in the activity of mitochondrial complex IV in the affected 
regions of human AD brains has been reported by post-mortem studies [320,321], indicating 
the contribution of energy impairment in the underlying pathology. In addition, AD patients 
appear to harbor numerous mtDNA mutations, which can severely impair mitochondrial 
transcription [322]. The dysregulation of mitochondrial dynamics in AD neurons has also 
been reported [323]. Both extracellular and intracellular Aβ are known to contribute to 
neurotoxicity, the most toxic forms are small soluble globular structures (reviewed in [324]). 
Among experimental conditions, Aβ preferentially accumulates in the mitochondria [325], 
where it is able to inhibit the activity of complex IV [326] and promote mtPTP formation 
[327]. The preferential ability of oligomeric Aβ to accumulate in the mitochondria is 
supposed to be partly due to its increased lipid permeability (reviewed in [328]); however, a 
selective transport mechanism by the translocase of the outer membrane (TOM) machinery 
[329] and intramitochondrial Aβ production have also been reported [330]. Additionally to 
the indirect elevation of ROS production through disrupted respiration, Aβ fragments per se 
generate free radicals [331]. The co-localization of the dense core plaques with the fluorescent 
signaling of free radicals well demonstrates the direct connection between Aβ and ROS [332]. 
The massive overproduction of ROS can increase the accumulation of Aβ vice versa, 
completing a vicious circle [331]. The level of intramitochondrial Aβ correlates with the 
extent of mitochondrial dysfunction and severity of cognitive impairment in transgenic AD 
mice [333]. Synaptosomes preferentially accumulate Aβ, and show increased sensitivity to 
Aβ-toxicity [334]. Recently, the crucial role of the amyloid β-binding alcohol dehydrogenase 
(ABAD) enzyme has been revealed as a potential direct molecular link between Aβ and 
mitochondrial pathologies [335], which includes the selective inhibition of complex IV, ROS 
generation, mitochondrial transition [336] and the inhibition of intramitochondrial Aβ 
degrading presequence peptidase (PreP) [337]. Aβ has also been shown to directly interact 
with cyclophilin D (CypD) and adenine nucleotide translocase (ANT) [338] hence promoting 
the assembly of mtPTP. Most recently, Aβ has been reported to disintegrate the anterograde 
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transport of synaptosomes, leading to the degeneration of the synapses [339]. Besides, 
amyloid precursor protein (APP) [340] and Aβ25-35 [341] inhibit the entry of nuclear encoded 
proteins including subunits essential for the correct assembly of respiratory complexes, which 
triggers further deterioration in mitochondrial function and more extensive ROS production. 
Intracellular Aβ severely affects the function of the proteasomal degradation system as well. 
This effect is exaggerated in the absence of parkin [342], which appears to promote the 
clearance of toxic Aβ1-42 [343]. Aβ can indirectly trigger the hyperphosphorylation of tau 
through the activation of glycogen synthase kinase-3beta (GSK-3β) and mitogen activated 
protein kinase (MAPK) [344,345], which results in the disintegration of axonal structure. 
Recent studies tend to support earlier observations [346,347] that the amount of Aβ and pTau 
burden within the brain is in direct correlation with the severity of cognitive impairment [348-
351], whereas plasma and CSF levels of Aβ have an inverse correlation [352-354]. The direct 
contribution of pTau to mitochondrial dysfunction has also been reported as P301L tau 
transgenic mice exhibit a decreased activity of complex I and decreased expression of 
complex V [355,356]. The involvement of the deregulation of metabolic master regulator and 
mitochondrial biogenesis enhancer PGC-1α has recently been demonstrated in AD pathology 
as well, as its expression is decreased in the hippocampus of AD patients [357]. 
 Epidemiological studies indicate that the regular intake of dietary 3-n PUFAs is 
associated with a decreased risk for AD [358]. 3-n PUFAs are involved in several 
mitochondrial processes such as gene expression, free radical production, mitochondrial 
apoptosis and calcium homeostasis (reviewed in [359]). The plasma level of the 3-n PUFA 
docosohexaenaic acid (DHA) – an essential neuronal membrane phospholipid component – 
has been reported to inversely correlate with the severity of cognitive decline in AD [360]. 
Accordingly, experimental depletion of 3-n PUFA causes behavioral alterations, evokes a 
marked loss in postsynaptic proteins [361] and in NMDAR subunits NR2A and NR2B, and 
triggers the activation of apoptotic caspases [362] in transgenic AD models. These effects can 
be prevented by the dietary administration of DHA. DHA has also been demonstrated to 
reduce amyloid burden and tau phosphorylation [363,364] and to improve cognition in 
transgenic AD mice [364]. These protective effects of DHA are proposed to be mediated by 
the elevation of ApoE receptor family member SorLa (LR11) [365], which is robustly 
downregulated in AD [366] and appears to be essential in the regulation of APP trafficking 
and intracellular Aβ accumulation [367]. Initial clinical trials with 3-n PUFA/DHA 
supplementation could only detect significant cognitive improvement in patients with mild 
cognitive impairment (MCI) [368,369] or with very mild cognitive dysfunction [370], but not 
with definitive AD. A subsequent clinical trial has also failed to show any cognitive benefit in 
AD [371]; however, subgroup analyses have revealed significantly lower declines in 
Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and Mini-Mental 
State Examination (MMSE) scores during the 18 months of investigation among ApoE4 non-
carrier patients, an allele which has been associated with increased risk for AD when present 
[372]. A phase I/II (NCT01058941) and a phase III clinical trial (MAPT) are currently 
ongoing to study the potential therapeutic efficacy of DHA through different lengths of 
observation period. 
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 Acetyl-L-carnitine has widely been tested in AD as well. In vitro and in vivo studies 
indicate that this compound could be of therapeutic use in AD since it potently reduces 
oxidative damage [373,374], restores metabolic changes [375], attenuates tau phosphorylation 
[376], protects against Aβ toxicity [373], and halts cognitive decline [374,376] in a wide 
range of AD models. Human trials from the early 1990s provided promising results with 
significantly slower rate of cognitive deterioration in many aspects [377-379]. A subsequent 
larger trial have failed to demonstrate any significant improvement [380]; however, there has 
been an observable tendency to slow the rapid deterioration of relatively younger patients 
with early-onset AD, which has proved to be statistically significant during the reanalysis of 
the data [381]. Unfortunately, in a subsequent prospective study acetyl-L-carnitine has failed 
to halt the decline in patients with young-onset AD [382]. Some recent results still seems to 
give hope, demonstrating that acetyl-L-carnitine improves the response rate of AD patients to 
acetylcholinesterase (AChE) inhibitor therapy [383], which is currently the first-line treatment 
in AD. Two recent clinical investigations run by the same research group have reported 
clinically observable improvement and maintenance in performance in many outcomes due to 
the administration of an antioxidant combination formula containing 500 mg acetyl-L-
carnitine [384,385]. An independent phase II clinical trial with MCI patients has just been 
finished (NCT00903695), while another phase II study with MCI and definitive AD patients 
(NCT01320527) is currently recruiting participants to confirm or deny the promising results 
of this formulation.  
 One of the biggest disappointments was the failure of a former non-selective anti-
histamine 2,8-dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-
b]indole hydrochloride (latrepirdine, Dimebon). Latrepirdine has provided neuroprotection 
and enhanced cognitive performance in a wide range of experimental models [386-388]. It is 
presumed to have multiple mechanisms of action that might include NMDAR inhibition 
[389], AchE inhibition [390], enhancement of cerebral glucose utilization [391] and the 
improvement of mitochondrial function [388], mediated partly by the inhibition of L-type 
Ca2+ channels [386]. However, its efficacy to inhibit mtPTP [392] has recently been 
questioned [393] along with the clinical relevance of its ability to block NMDARs and AChE 
[387]. The initial human investigations have demonstrated unusually promising results with a 
phase II clinical trial (NCT00377715) reporting significant improvement in all primary and 
secondary outcomes [394]. In contrast, the results of a phase III efficacy and safety study 
(CONNECTION) have recently been announced reporting zero benefit in any endpoint [395]. 
Several phase III trials with latrepirdine have subsequently been terminated (CONTACT, 
NCT00912288, NCT00939783), one has just been completed (NCT00838110) and another 
one is still ongoing to elucidate its efficacy in AD patients on Donepezil treatment 
(CONCERT). It might be possible that the apparent ability of latrepirdine to increase 
cognitive performance is achieved through mechanisms not necessarily involved in the 
pathology of AD, which is in line with the recent findings that this efficacy of latrepirdine is 
unrelated to cerebral Aβ burden in transgenic AD mice [396], but it is also apparent in healthy 
animals [396,397]. The robust discrepancies between preclinical and clinical examinations, 
and also between two independent clinical trials raise serious concerns about the correct 
interpretation of preclinical findings.  
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AD and the kynurenine system 
The distribution of the pathological hallmarks of AD in the brain is consistent with the 
regions of memory formation, where the glutamatergic circuitry is fundamental. One of the 
most affected structures is the hippocampal formation. Hippocampus, and particularly cornu 
ammonis 1 (CA1) [398], is known to be extremely vulnerable to a wide range of insults 
including glutamatergic excitotoxicity (reviewed in [399]), at least in part due to the high 
concentration of exctitatory amino acid receptors. Experimental AD models provide evidence 
that the presence of Aβ1-42 further increases neuronal vulnerability to excitotoxic stress 
[400,401]. Furthermore, Aβ1-42, but not Aβ1-40, significantly induces the expression of 
indoleamine 2,3-dioxygenase 1 (IDO1) and the production of QUIN [402], which are both 
abundantly present in AD hippocampus with the highest abundance in the perimeter Aβ senile 
plaques [403] and in specific conjunction with NFTs [404]. The increased production of 
QUIN in AD brain has been associated with the need for inflammatory circumstances being 
present [405,406], which is in line with the recent findings that Aβ1-42 pre-treatment primes 
only a slight induction of IDO expression in in vitro microglia models, and the robust 
activation can only be seen after the administration of the pro-inflammatory cytokine 
interferon-γ to the Aβ1-42 pre-treated cells [407]. QUIN has a high affinity towards inducing 
lipid peroxidation [408], which corresponds with the observations that lipid peroxidation is a 
characteristic feature of AD but not of normal aging (reviewed in [409]). There is 
considerable evidence that QUIN also contributes to the hyperphosphorylation of tau proteins 
via the overactivation of NMDARs [410]. These findings substantially overwrite the 
conclusions from earlier observations that QUIN would not play a crucial role in the 
development of neurodegeneration in AD. 
 The findings regarding KYNA are not that concording. Although decreased KYNA 
levels were found in the blood [411] and CSF [309] of AD patients, marked elevation in 
KYNA concentrations was detected in the striatum with increased KAT I and KAT II 
activities, and also slight elevation in the hippocampus with no KAT alterations [412]. The 
elevation of KYNA might be due compensatory mechanisms and can contribute to the 
cognitive impairment [413-415] as it is suggested also in Down syndrome and schizophrenia. 
There is considerable evidence that the modulation of QUIN synthesis can offer 
neuroprotection in animal models of AD. Recently the novel KMO inhibitor prodrug JM6 has 
been reported to be effective in preventing spatial memory deficits, anxiety behavior, and 
synaptic loss in transgenic AD mice [112]. In experimental conditions, the systemic 
administration of probenecid with L-KYN as an immediate metabolic precursor of KYNA 
exerts neuroprotection against intrahippocampal Aβ25-35 [102]. Similar effects have been 
reported about 4-Cl-KYN against QUIN induced hippocampal toxicity [87]. However, the 
therapeutic relevance of these approaches in AD might be questioned with respect to the 
arising evidence that elevated KYNA levels are involved in the cognitive decline in AD. It 
seems reasonable that the treatment of AD via the modulation of TRP metabolism will require 
the most sophisticated pharmaceutical approache that includes, on the one hand, the inhibition 
of QUIN synthesis to provide neuroprotection against excitotoxic insults, and on the other 
hand, the reduction of excessive KYNA levels to offer proper NMDAR function for adequate 
memory formation and recall [414,415]. 
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Figure 3. Mitochondria in neurodegenerative diseases 
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The figure presents the schematic overview of the processes involved in mitochondrial 
dysfunction related to Parkinson’s, Huntington’s and Alzheimer’s diseases. For detailed 
description, we refer to the corresponding parts of the article.  
↑ = increased presence/expression/activity; ↓ = decreased presence/expression/activity; arrow 
= promotion; bulb-headed arrow = inhibition/deterioration; I-V = mitochondrial complexes; 
3NP = 3-nitropropionic acid; Aβ = β-amyloid (toxic isoforms); ABAD = amyloid β-binding 
alcohol dehydrogenase; BDNF = brain-derived neurotrophic factor; c = cytochrome c; CREB 
= cyclic AMP response element-binding protein; γ = gamma secretase; HtrA2/Omi = high 
temperature requirement factor A2; IC Ca2+= intracellular calcium; LRRK2 = leucine-rich 
repeat kinase 2; MPP+ = 1-methyl-4-phenylpyridinium; mt Ca2+= mitochondrial calcium; 
mtDNA = mitochondrial DNA; mtNOS = mitochondrial nitric oxide synthase; NEMP = 
nuclear-encoded mitochondrial protein; NMDAR = N-methyl-D-aspartate-sensitive glutamate 
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receptor; PINK1 = (PTEN)-induced putative kinase 1; PGC-1α = PPARγ coactivator-1α; 
POLG1 = mtDNA polymerase gamma 1; PreP = presequence peptidase; pTau = 
hyperphosphorylated tau protein; Q = coenzyme Q10 (ubiquinone); QUIN = quinolinic acid; 
ROS = reactive oxygen species; TFAM = mitochondrial transcription factor A; TIM = 
translocase of the inner membrane; TOM = translocase of the outer membrane. 
CONCLUDING REMARKS 
 The pathogenesis of common neurodegenerative disorders such as PD, HD and AD is 
robustly associated with mitochondrial dysfunction. The putative origins of these diseases are 
distinct; however, the shared contribution of mitochondrial dysfunction can lead to certain 
extent of symptomatic overlap in the terminal phases of the clinical pathology. The 
underlying causes behind the preferential involvement of particular CNS regions in these 
diseases require further elucidation; however, it can be concluded that the extreme energy 
demand of the affected structures make them highly vulnerable to any sort of mitochondrial 
disturbances. Mitochondria targeted therapies aiming to overcome the energy impairment and 
the extensive oxidative stress show great promises in a wide range of experimental conditions. 
Unfortunately, the results gained from human clinical trails are rather disappointing or at best 
very controversial. One of the reasons underlying this phenomenon can be the extreme 
genetic and conditional homogeneity of the experimental animals in contrast to the 
heterogeneity of the clinical population usually recruited in a trial. Another concern is the 
relatively young age of animals applied for the experimental setups versus the relatively aged 
subjects of the clinical trials. This can lead to false positive results in terms of neuroprotection 
in vivo, since younger animals can be more resistant to the experimentally induced 
mitochondrial toxicity, thus the protective effect of a drug candidate can be more pronounced. 
Thirdly, most of the preclinical investigations focus on the prevention or reduction of the 
neurodegenerative effect of the applied toxin or genetic alteration, which is obviously unable 
to model the status of trial participants, who have already suffered an extensive loss of 
neurons in the affected CNS regions by the time of the diagnosis. These shortcomings are to 
be considered in the future during the setup of both in vivo examinations and human trials.  
 Considering that NMDAR-mediated excitotixicity seems to be ubiquitous in 
neurodegenerative disorders, and that the affected structures possess anatomical and 
physiological susceptibility to be highly sensitive to this process, the investigation of the 
kynurenine system as the endogenous regulator of NMDAR functioning is of great interest. 
May the alterations in TRP metabolism be rather secondary to the underlying pathological 
processes, it can be concluded that the local decrease in KYNA and the local elevation in 
QUIN and 3-OH-L-KYN levels can contribute to neurodegeneration through the 
overactivation of NMDARs. Alzheimer’s disease might be an exception where the elevation 
of KYNA levels in the affected structures has been reported, which probably contributes to 
the development of cognitive decline. Promising experimental results have come to rise in the 
near past in different models of neurodegenerative diseases through the exogenous regulation 
of TRP metabolism. The application of novel KYNA analogues and KMO inhibitors show the 
greatest therapeutic promise. Thorough examinations and well set-up human trials are 
warranted to elucidate the therapeutic potential of these candidates. 
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LIST OF ABBREVIATIONS 
3-HAO = 3-hydroxyanthranic acid 3,4-dioxygenase; 3NP = 3-nitropropionic acid; 3-OH-
ANA = 3-hydroxy-anthranilic acid; 3-OH-L-KYN = 3-hydroxy-L-kynurenine; ; Aβ = β-
amyloid ; ABAD = amyloid β-binding alcohol dehydrogenase; AChE = acetylcholinesterase; 
AD = Alzheimer’s disease; ADAS-cog = Alzheimer's Disease Assessment Scale cognitive 
subscale; AIF = apoptosis-inducing factor; ANA = anthranilic acid, ANT = adenine 
nucleotide translocase; Apaf-1 = apoptotic protease activating factor 1; APP = amyloid 
precursor protein; BBB = blood–brain barrier; BDNF = brain-derived neurotrophic factor; 
CA1 = cornu ammonis 1; CREB = cyclic AMP response element-binding protein; CSF = 
cerebrospinal fluid; CypD = cyclophilin D; DHA = docosohexaenaic acid; EPA = 
eicosapentaenic acid; GABA = γ-aminobutyric acid; GSK-3β = glycogen synthase kinase-
3beta; H2O2 = hydrogen peroxide; HD = Huntington’s disease; HtrA2 = high temperature 
requirement factor A2 (Omi); IDO = indoleamine 2,3-dioxygenase; IT15 = interesting 
transcript 15; JM6 = 2-(3,4-dimethoxybenzenesulfonylamino)-4-(3-nitrophenyl)-5-(piperidin-
1-yl)methylthiazole; KAT = kynurenine aminotransferase; KMO = kynurenine 3-
monooxygenase (kynurenine 3-hydroxylase); KYNA = kynurenic acid; latrepirdine = 2,8-
dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-
b]indole hydrochloride; L-KYN = L-kynurenine; LRRK2 = leucine-rich repeat kinase 2; 
MAPK = mitogen activated protein kinase; MCI = mild cognitive impairment; MMSE = 
Mini-Mental State Examination; MnSOD = manganese superoxide dismutase; MPP+ = 1-
methyl-4-phenylpyridinium; MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MSN = 
medium-sized spiny neuron; mtAAT = aspartate aminotransferase; mtDNA = mitochondrial 
DNA; mtNOS = mitochondrial nitric oxide synthase; mtPTP = mitochondrial permeability 
transition pore; NCR-631 = 4,6-dibromo-3-OH-ANA; nDNA = nuclear DNA; NFT = 
neurofibrillary tangle; NMDA = N-methyl-D-aspartate; NMDAR = N-methyl-D-aspartate-
sensitive glutamate receptor; nNOS = neuronal nitric oxide synthase; NO• = nitric oxide 
radical; NOS = nitric oxide synthase; O2–• = superoxide anion; OH–• = hydroxyl radical; 
PARP-1 = poly(ADP-ribose) polymerase-1; PD = Parkinson’s disease; PGC-1α = PPARγ 
coactivator-1α; PINK1 = (PTEN)-induced putative kinase 1; PNU 156561 = 4,5-
dichlorobenzoylalanine (FCE 288833A); POLG1 = mtDNA polymerase gamma 1; polyQ = 
polyglutamine; PPARγ = peroxisome proliferator-activated receptor-γ; PreP = presequence 
peptidase; PSD-95 = postsynaptic density protein of molecular weight 95 kDa; pTau = 
hyperphosphorylated tau protein; PUFA = polyunsaturated fatty acid; QUIN = quinolinic 
acid; Ro 61-8048 = 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2-yl]-benzenesulfonamide; 
ROS = reactive oxygen species; SNP = single nucleotide polymorphism; SNpc = substantia 
nigra pars compacta; TFAM = mitochondrial transcription factor A; TIM = translocase of the 
inner membrane; TOM = translocase of the outer membrane; TRAP1 = tumor necrosis factor 
receptor-associated protein 1; TRP = tryptophan; UPF 648 = (1S,2S)-2-(3,4-dichlorobenzoyl)-
cyclopropane-1-carboxylic acid. 
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